Skip to main content

Table 1 Brief chronology of the key clinical events in this case

From: Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma

Time before and after
CAR T cell therapy
DateKey events
−5 years2014/7Diagnosis of DLBCL
−5 to −0.5 years2014/7 to 2018/18 cycles of R-CHOP and sustained remission
−1 year2017/7Discontinuation of entecavir
−6 months2018/1Relapse/reintroduction of entecavir
−4 days to −2 days2018/6/29 to 2018/7/1Standard lymphodepleting chemotherapy regimen
0 days2018/7/3Start of CART therapy
0 days to + 3 days2018/7/3 to 2018/7/6Sequential infusion of anti-CD 19 and anti-CD22 CAR T cell therapy
+ 4 weeks2018/8/4Discontinuation of entecavir
+ 9 weeks2018/9/4Activation of hepatitis B
+ 3.3 months2018/10/12Death